Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Zinc study #48   All Outcomes
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mechanical ventilation -14% Imp. Relative Risk, 95% CI ICU admission -14% Hospitalization -14% Kaplan: Resveratrol and Zinc in the Treatment of Outpatients Wit.. c19zinc.com/kaplan.html Favors zinc Favors control
10/1 Late treatment study
Kaplan et al., SSRN, 10.2139/ssrn.3934228 (Preprint)
Resveratrol and Zinc in the Treatment of Outpatients With COVID-19 – The Reszinate Study - A Phase 1/2 Randomized Clinical Trial Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling
Source   PDF   Share   Tweet
Small RCT of zinc plus resveratrol in COVID-19+ outpatients, not showing significant differences in viral clearance or symptoms. There was a non- statistically significant trend toward more rapid decrease in symptoms in the treatment group. Although the treatment group was older (46.3 vs. 38.5) and had more severe baseline symptoms, they had similar symptomatic recovery by the second week.
risk of mechanical ventilation, 14.3% higher, RR 1.14, p = 1.00, treatment 1 of 14 (7.1%), control 1 of 16 (6.2%).
risk of ICU admission, 14.3% higher, RR 1.14, p = 1.00, treatment 1 of 14 (7.1%), control 1 of 16 (6.2%).
risk of hospitalization, 14.3% higher, RR 1.14, p = 1.00, treatment 1 of 14 (7.1%), control 1 of 16 (6.2%).
Kaplan et al., 10/1/2021, Randomized Controlled Trial, USA, North America, preprint, 12 authors, this trial uses multiple treatments in the treatment arm (combined with resveratrol) - results of individual treatments may vary.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit